Abstract
Background
Cardiotoxicity associated with 5-Fluorouracil (5FU) administration has been infrequently reported in literature, albeit various series of acute coronary syndromes have recorded a low but definite incidence of the above toxicity. In the present study, patients undergoing 5FU-based and oral capecitabine (Xeloda®)-based chemotherapy were tested for the potential development of cardiac-related symptoms during their administration.
Patients and methods
Six hundred and forty-four patients entered the study. Those experiencing any cardiac-related symptoms during 5FU infusion or oral capecitabine were subjected to ECG and serum cardiac enzymes determination. If cardiotoxicity was confirmed, 5FU infusion or oral capecitabine were interrupted, sublingual nitrates administered and cardiac monitoring initiated, while patients with >two-fold enzyme elevation were followed in a coronary care unit for at least 72 h. Cases with acute myocardial infarction were excluded from further 5FU or oral capecitabine treatment.
Results
Overall 26 patients (4.03%) developed symptoms and/or ECG abnormalities due to 5FU and capecitabine. Patients with continuous 5FU infusion presented a higher incidence of cardiotoxicity [14/209; 6.7%, 95% confidence interval (CI) = 3.3–10.1%] than the remaining (7/317; 2.3%, 95% CI = 0.8–3.3%) (P < 0.012). Specifically, an increased incidence of cardiac-related events was encountered in patients with continuous 24-h 5FU + LV infusion for 5 days (12.5%, 95% CI = 2.3–22.7%) rather than in patients with the same schedule without LV (5.3%, 95% CI = 1.95–8.67%) (P < 0.027), as well as in patients with short 5FU + LV administration (2.4%, 95% CI = 0.9–3.9%) (P < 0.019). Overall, 3/54 patients (5.5%, 95% CI = −0.6–11.1%) on oral capecitabine developed cardiac-related events. Seven out of the 20 patients suffered an acute myocardial infarction, 6 developed ischemia only, while 4 more patients had ECG consistent with coronary vasospasm and 3 with conduction disturbances, of which one subsequently died. Patients administered oral capecitabine had a similar incidence of cardiac-related events; 1/22 (4.5%) patients with advanced breast cancer and 2/32 (6.2%) with colorectal cancer.
Conclusions
The present study supports the toxic effect of 5-FU on the myocardium, which is largely schedule-dependent, whereas a low but finite risk of such toxicity has been observed with oral capecitabine. A high level of alertness is required when using fluoropyrimidines (i.v. 5FU or oral capecitabine), while their toxic effect on the coronary endothelium and myocardium merits further investigation.
Similar content being viewed by others
References
Akhtar SS, Salim KP, Bano ZA (1993) Symptomatic cardiotoxicity with high-dose 5-fluorouracil infusion: a prospective study. Oncology 50:441–444
Blum RH, Carter SK (1974) Adriamycin: a new anticancer drug with significant clinical activicy. Ann Intern Med 80:249–259
Cwikiel M, Zhang B, Eskilsson J, Wieslander JB, Albertsson M (1995) The influence of 5-fluorouracil on the endothelium in small arteries. An electron microscopic study in rabbits. Scanning Microsc 9:561–576
Cwikiel M, Eskilsson J, Albertsson M, Stavenow L (1996a) The influence of 5-fluorouracil and methotrexate on vascular endothelium. An experimental study using endothelial cells in the culture. Ann Oncol 7:731–737
Cwikiel M, Eskilsson J, Wieslander JB, Stjernquist U, Albertsson M (1996b) The appearance of endothelium in small arteries after the treatment with 5-fluorouracil. An electron microscopic study of late effects in rabbits. Scan Micros 10:187–192
De Forni M, Malet-Martino MC, Jaillais P, Shubinski RE, Bachaud JM, Lemaire L, Canal P, Chevreau C, Carrie D, Soulie P (1992) Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol 10:1795–1801
Freeman N, Costanza M (1998) 5-Fluorouracil-associated cardiotoxicity. Cancer 61:36–45
Frickhofen N, Beck FJ, Jung B, Fuhr HG, Andrasch H, Sigmund H (2002) Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil. Ann Oncol 13:797–801
Gaveau T, Banzet P, Marneffe H, Viars P (1969) Traubles cardiovasculaires au cours d’infusions d’anti-mitociques a fortes doses: 30 observacions cliniques. Anaesth Analg (Paris) 26:311–327
Grandi AM, Pinotti G, Morandi E, Zanzi P, Bulgheroni P, Guasti L, Bertolini A, Venco A (1997) Noninvasive evaluation of cardiotoxicity of 5-fluorouracil and low doses of folinic acid: a one-year follow-up study. Ann Oncol 8:705–708
Grem JL (1996) 5-Fluoropyrimidines. In: Chabner BA, Longo DL (eds) Cancer chemotherapy and biotherapy: principles and practice, 2nd edn. Lippincott-Raven, Philadelphia, p 149
Jensen SA, Sorensen JB (2006) Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine. Cancer Chemother Pharmacol 58:487–493
Labianca R, Beretta G, Clerici M, Fraschini P, Luporini G (1982) Cardiac toxicity of 5-fluorouracil: a study on 1083 patients. Tumori 68:505–510
Lemaire L, Malet-Martino MC, Longo S, Martino R, de Forni M, Carton M (1991) Fluoroacetate as cardiotoxic impurity in fluorouracil (Roche). Lancet 337:560
Levillain R (1972) Experimental myocarditis; anatomical study of 210 rat hearts after ingestion of 5-fluorouracil. C R Seances Soc Biol Fil 166:340–342
Matsubara I, Kamiya J, Imai S (1980) Cardiotoxic effects of 5-fluorouracil in the guinea pig. Jpn J Pharmacol 30:871–879
Meyer CC, Calis KA, Burke LB, Walawander CA, Grasela TH (1997) Symptomatic cardiotoxicity associated with 5-fluorouracil. Pharmacotherapy 17:729–736
Moertel CG Reitermeier RJ (1962) Experience with 5-Fluoruracil in the palliative management of advanced carcinoma of the gastrointestinal track. Staff meeting of the Mayo Clinic. Mayo Clinic Proc 37:520–529
Mosseri M, Fingert HJ, Varticovski L, Chokshi S, Isner JM (1993) In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle. Cancer Res 53:3028–3033
Porta C, Moroni M, Ferrari S, Nastasi G (1998) Endothelin-1 and 5-fluorouracil induced cardiotoxicity. Neoplasma 45:81–82
Pottage A, Holt S, Ludgate S, Langlands AO (1978) Fluorouracil cardiotoxicity. Br Med J 1:547
Rezkalla S, Kloner RA, Ensley J, al-Sarraf M, Revels S, Olivenstein A, Bhasin S, Kerpel-Fronious S, Turi ZG (1989) Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study. J Clin Oncol 7:509–514
Roth A, Kolaric K, Popovic S (1975) Cardiotoxicity of 5-fluorouracil (NSC 1993). Cancer Chemother Rep 59:1051–1052
Sasson Z, Morgan CD, Wang B, Thomas G, MacKenzie B, Platts ME (1994) 5-Fluorouracil related toxic myocarditis: case reports and pathological confirmation. Can J Carrdiol 10:861–864
Schöber C, Schmoll HJ, Papageorgiou E (1993) Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer. Cancer 72:2243–2247
Soukop M, McVie JG, Calman KC (1978) Flouorouracil cardiotoxicity. Br Med J 1:1422
Stevenson D, Mikhailidis D, Gillett D (1977) Cardiotoxicity of 5-fluorouracil. Lancet 2:406–407
Van Cutsem E, Hoff PM, Blum JL, Abt M, Osterwalder B (2002) Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil. Ann Oncol 13:484–485
Villani F, Guindani A, Pagnoni A (1979) 5-fluorauracil cardiotoxicity. Tumori 65:487–495
von Hoff DD, Rozencweig M, Layard M, Slavik M, Muggia FM (1977) Daunomycin induced cardiotoxicity in children and adults: a review of 110 cases. Am J Med 62:200–208
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kosmas, C., Kallistratos, M.S., Kopterides, P. et al. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol 134, 75–82 (2008). https://doi.org/10.1007/s00432-007-0250-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-007-0250-9